Symbols

HOTH

Hoth Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HOTH

Hoth Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing the treatment for cancer, anaphylaxis, traumatic brain injury, ischemic stroke, or other neuroinflammatory diseases

Industry

Pharmaceutical

Established Date

05/16/2017

Listing Date

02/15/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.hoththerapeutics.com

Security Type

Common stock

Office address

720 Monroe Street Suite E514 Hoboken NJ 07030

Business

Introduction

Hoth Therapeutics, Inc., was incorporated under the laws of the State of Nevada on May 16, 2017. The company is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for unmet medical needs. Its R&D pipeline includes drug candidates for tumor treatment-related side effects, mast cell-derived cancers, neuroinflammatory diseases and other indications.

Company Financials

EPS

HOTH has released its 2025 Q2 earnings. EPS was reported at -0.17, versus the expected -0.31, beating expectations. The chart below visualizes how HOTH has performed over recent quarters, highlighting trends in earnings surprises.